Leading institutions, such as 50% of the top 20 hospitals ranked by U.S. News & World Report and the U.S. Navy, use the Intercept Blood System for Platelets to help reduce the risk of pathogens in platelets Leading institutions are already using INTERCEPT® Blood System

50% of the top 20 hospitals as ranked by U.S. News & World Report use the INTERCEPT Blood System for platelets to reduce the risk of blood-borne pathogens for their transfusion patients50% of the top 20 hospitals as ranked by U.S. News & World Report use the INTERCEPT Blood System for platelets to reduce the risk of blood-borne pathogens for their transfusion patients

The U.S. Navy has adopted the INTERCEPT Blood System for all apheresis platelet collections as of December 31, 2018The U.S. Navy has adopted the INTERCEPT Blood System for all apheresis platelet collections as of December 31, 20181

Blood-borne pathogens are a real risk

Every year, more than 2.5 million platelet transfusions are vital for patient care in the U.S.2 But if those platelets contain pathogens, that life-saving therapy can turn deadly quickly—especially for immunocompromised patients.

Studies show

  • Bacteria-contaminated platelets continue to be transfused3-6
  • Transfusion reactions and related sepsis events are under-reported7
  • Conventional platelet transfusion has known and unknown viral and parasite risks including West Nile, Zika, Yellow Fever, Babesia, Chikungunya, Dengue, and Malaria
    – Testing for these pathogens individually is costly and time-consuming8-10

Platelets are stored at room temperature for several days, providing an ample environment for bacterial growth, leukocyte cytokine production, and virus and parasite survival.

Blood-borne pathogens are a real risk to patients; if platelets used in platelet transfusions contain pathogens, that life-saving therapy can turn deadly quickly—especially for immunocompromised patients.

Infection Risks

For patients

Sepsis is the #1 risk from contaminated platelet transfusions

A recent investigation into 3 deaths from platelet transfusion-associated bacterial sepsis revealed that—even when following current procedures—the risk for transfusion-related infection and fatalities persists, making interventions such as pathogen reduction vital.12

Transfusion-transmitted bacterial infections are likely under-diagnosed because recipients often receive broad-spectrum antibiotics or antipyretics, have underlying medical conditions that increase sepsis risk, or the septic reaction might not be attributed to the transfusion.7

Infection Risks

For the healthcare system

At an average cost of $80,000 per patient, sepsis is one of the most expensive conditions to treat in the U.S. It costs the healthcare system approximately $24 billion per year.13

It is estimated that 30-50% of sepsis patients do not survive

The most common patient platelet usage includes hematology, oncology, cardiothoracic surgery, organ transplants, intensive care unit, pediatrics, neonates, and massive transfusion protocols

More than half (50%) of platelet transfusion patients are severely immunocompromised

  • Infection Risks

    • For patients

    • For the healthcare system

Sepsis is the #1 risk from contaminated platelet transfusions

A recent investigation into 3 deaths from platelet transfusion-associated bacterial sepsis revealed that—even when following current procedures—the risk for transfusion-related infection and fatalities persists, making interventions such as pathogen reduction vital.12

Transfusion-transmitted bacterial infections are likely under-diagnosed because recipients often receive broad-spectrum antibiotics or antipyretics, have underlying medical conditions that increase sepsis risk, or the septic reaction might not be attributed to the transfusion.7

At an average cost of $80,000 per patient, sepsis is one of the most expensive conditions to treat in the U.S. It costs the healthcare system approximately $24 billion per year.13

It is estimated that 30-50% of sepsis patients do not survive

The most common patient platelet usage includes hematology, oncology, cardiothoracic surgery, organ transplants, intensive care unit, pediatrics, neonates, and massive transfusion protocols

More than half (50%) of platelet transfusion patients are severely immunocompromised

INTERCEPT Blood System is proven to reduce the risk of transfusion-transmitted infection and help protect patients15

The INTERCEPT Blood System is the only pathogen reduction solution for platelets approved by the Food and Drug Administration (FDA). The system is proven to provide broad spectrum reduction of blood-borne pathogens—before they reach patients.
 

The INTERCEPT Blood System for Platelets

  • Offers a broad spectrum of pathogen reduction including viruses, bacteria, parasites, and donor T-cells by targeting DNA and RNA
  • Is the only FDA-approved pathogen reduction technology for reducing transfusion-transmitted risk from emerging pathogens like Zika virus16
  • Eliminates the need for primary bacterial culture
  • Approved by the FDA and meets requirement of AABB Standard 5.19.3.1 as an alternative to gamma irradiation for the prevention of TA-GVHD
  • Inactivates cytomegalovirus (CMV)—meets the AABB Standard 5.19.2 policy requiring methods to reduce transmission risk

Reducing risk for patients has never been easier

For clinicians and hospitals, INTERCEPT platelets are transfusion-ready and require no change in current protocol. Platelets are ordered from your blood bank and received through normal supply chain processes.

 

For more information about the INTERCEPT Blood System for platelets, visit hcp.intercept-usa.com/.

The INTERCEPT Blood System for Platelets

  • Offers a broad spectrum of pathogen reduction including viruses, bacteria, parasites, and donor T-cells by targeting DNA and RNA
  • Is the only FDA-approved pathogen reduction technology for reducing transfusion-transmitted risk from emerging pathogens like Zika virus16
  • Eliminates the need for primary bacterial culture
  • Approved by the FDA and meets requirement of AABB Standard 5.19.3.1 as an alternative to gamma irradiation for the prevention of TA-GVHD
  • Inactivates cytomegalovirus (CMV)—meets the AABB Standard 5.19.2 policy requiring methods to reduce transmission risk
Intercept Blood System is the only FDA-approved pathogen reduction solution for platelets that provides broad-spectrum reduction of pathogen in platelets.

Reducing risk for patients has never been easier

For clinicians and hospitals, INTERCEPT platelets are transfusion-ready and require no change in current protocol. Platelets are ordered from your blood bank and received through normal supply chain processes.

Help protect your blood supply and your patients

Learn how to reduce the risk of transfusion-related infections in your health system. Download a presentation by completing the form below.
 

Contact Us

 

References
1. Pathogen Reduction Technology for Apheresis Platelets. BUMED INSTRUCTION 6530.16, Department of the Navy, July 3, 2018. http://www.med.navy.mil/directives/Pages/BUMEDinstructions.aspx
2. Ellingson KD, et al. Transfusion. 2017 Jun; 57 Suppl 2:1588-1598.
3. Dumont LJ, et al. Transfusion. 2010 Mar; 50(3):589–99.
4. Pearce S, et al. Transfus Med. 2011 Feb; 21(1):25–32.
5. Murphy WG, et al. Vox Sang. 2008 Jul; 95(1)13–9.
6. Walther-Wenke G, et al. Vox Sang. 2011 May;100(4):359–66.
7. Hong H, et al. Blood 2016: 127(4) 496-502.
8. Ellingson K, Sapiano, M, Haass K, et al. Cost projections for implementation of safety interventions to prevent transfusion-transmitted Zika virus infection in the United States. Transfusion 2017;57:1625-33.
9. Korves CT, Goldie SJ, Murray MB. Cost-effectiveness of alternative blood-screening strategies for West Nile Virus in the United States. PLoS medicine 2006;3:e21.
10. Moreno-Madrinan MJ, Turell M. History of Mosquito borne Diseases in the United States and Implications for New Pathogens. Emerg Infect Dis 2018;24:821-6.
11. Kleinman S, et al. Transfusion 2013; 53:1603-1618.
12. Horth RZ, Jones JM, Kim JJ, et al. Fatal sepsis associated with bacterial contamination of platelets—Utah and California, August 2017. Morbidity and Mortality Weekly Report 2018; 67(25): 718-722.
13. June 2016 statistical brief from the Healthcare Cost and Utilization Project (HCUP) and the Agency for Healthcare Research and Quality, a division of the U.S. Department of Health and Human Services. (2013 vs. 2011 analysis)
14. Fleischmann, C., et al. Hospital Incidence and Mortality Rates of Sepsis. Deutsches Arzteblatt International 113, 159-166 (2016).
15. Benjamin RJ, Braschler T, Weingand T, Corash LM. Transfusion 2017;57:2946-57.
16. FDA. Revised Recommendations for Reducing the Risk of Zika Virus Transmission by Blood and Blood Components. FDA Guidance for Industry July 2018.